Clinical Trial Update: BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes [Phase 2]

View source ↗

Summary

Phase 2 BrUOG 337 trial evaluating olaparib before radical prostatectomy in advanced prostate cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Brown University | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: TERMINATED | Results posted: 2022-02-03